CLARENCE CHU: Open Payments
NPI 1891231924 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,137 in 108 payments from 18 companies in 2025. Trend: 2023 $6,678 · 2024 $7,466 · 2025 $5,137
Food & beverage: $5,087Education: $50
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 14 | $774 |
| Organon LLC | 7 | $653 |
| GENZYME CORPORATION | 5 | $550 |
| ABBVIE INC. | 14 | $499 |
| LEO Pharma Inc. | 10 | $450 |
| PFIZER INC. | 9 | $386 |
| Novartis Pharmaceuticals Corporation | 5 | $352 |
| Incyte Corporation | 9 | $334 |
| Arcutis Biotherapeutics, Inc. | 12 | $288 |
| Regeneron Healthcare Solutions, Inc. | 5 | $151 |
Products named: NEMLUVIO, DUPIXENT, VTAMA, ADBRY, OPZELURA, Zoryve, CIBINQO, BOTOX.
Industry payments across CA — which companies pay providers there.
